In back-to-back fail­ures, An­thera’s CF drug Sollpu­ra falls short in PhI­II, shares crater (again)

Six weeks af­ter An­thera $ANTH suf­fered a failed Phase III study for its lu­pus drug blis­i­bi­mod, the small biotech was forced to con­cede that its late-stage non-in­fe­ri­or­i­ty study for its cys­tic fi­bro­sis drug Sollpu­ra al­so flopped.

Held out as An­thera’s best chance at bounc­ing back in 2017, Sollpu­ra failed to hit the pri­ma­ry end­point on non-in­fe­ri­or­i­ty for change in the Co­ef­fi­cient of Fat Ab­sorp­tion, or CFA. The com­pa­ny added that the drug hit the goal in a per pro­to­col analy­sis — fac­tor­ing in on­ly the pa­tients who com­plet­ed the study — and al­so hit on a Co­ef­fi­cient of Ni­tro­gen Ab­sorp­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER